Search Results 481-490 of 17367 for alopecia

1. Science Saturday: A year of new directions and advancements for regenerative medicine - Mayo Clinic News Network

   Regenerative procedures, such as platelet-rich plasma to rejuvenate aging skin and stimulate hair growth for people with alopecia or baldness, are offered on ...

2. Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

3. Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma - Mayo Clinic

   ... alopecia. Exclusion Criteria: Ability to understand the study procedures and provide written informed consent. Negative hepatitis B test (defined by a ...

4. A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus - Mayo Clinic

   All toxicities related to previous anti-cancer therapies have resolved ≤ CTCAE Grade 1 prior to trial treatment administration (except for alopecia and ...

5. Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. Known immediate or delayed ...

6. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

   recovered from adverse events (other than alopecia or neuropathy) due to agents administered more than 4 weeks earlier. However, the following therapies are ...

7. Safety Study of SEA-CD40 in Cancer Patients - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy (excluding alopecia) prior to initiation of study drug ...

8. A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma - Mayo Clinic

   ... alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment. Radiation therapy administered within 2 weeks ...

9. Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors - Mayo Clinic

   ... alopecia -Receiving any other investigational agents =< 28 days prior to registration -Known brain metastases (even if treated) -Known portal hypertension ...

10. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

    * Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.